Among patients with cirrhosis, recovery of liver function after SVR to all-oral directacting antivirals (DAA) in HIV/HCV coinfection could be different to that in HCV monoinfection. Because of this, we compared the changes in several markers of liver function between HCV-monoinfected and HIV/HCV-coinfected patients with cirrhosis who achieved SVR12 to DAA combinations. In this retrospective cohort study, cirrhotics included in the HEPAVIR-DAA and GEHEP-MONO cohorts were selected if they had SVR12 to all-oral DAAs. Patients treated with atazanavir were excluded. Liver function improvement was defined as Child-Pugh-Turcotte (CPT) decrease ≥1 and/or MELD decrease ≥2 between baseline and SVR12. Liver function worsening was defined as a CPT increase ≥1 and/or MELD increase ≥2 and/or decompensations between baseline and SVR12. We included 490 patients, 270 (55%) of them with HIV coinfection. Liver function improved in 50 (56%) HCV-infected individuals and in 82 (57%) HIV/HCV-coinfected patients (P = 0.835). Liver function worsened in 33 (15%) HCV-monoinfected patients and in 33 (13%) HIV/HCV-coinfected patients (P = 0.370).
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Summary
Among patients with cirrhosis, recovery of liver function after SVR to all-oral directacting antivirals (DAA) in HIV/HCV coinfection could be different to that in HCV monoinfection. Because of this, we compared the changes in several markers of liver function between HCV-monoinfected and HIV/HCV-coinfected patients with cirrhosis who achieved SVR12 to DAA combinations. In this retrospective cohort study, cirrhotics included in the HEPAVIR-DAA and GEHEP-MONO cohorts were selected if they had SVR12 to all-oral DAAs. Patients treated with atazanavir were excluded. Liver function improvement was defined as Child-Pugh-Turcotte (CPT) decrease ≥1 and/or MELD decrease ≥2 between baseline and SVR12. Liver function worsening was defined as a CPT increase ≥1 and/or MELD increase ≥2 and/or decompensations between baseline and SVR12. We included 490 patients, 270 (55%) of them with HIV coinfection. Liver function improved in 50 (56%) HCV-infected individuals and in 82 (57%) HIV/HCV-coinfected patients (P = 0.835). Liver function worsened in 33 (15%) HCV-monoinfected patients and in 33 (13%) HIV/HCV-coinfected patients (P = 0.370).
Factors independently related with liver function improvement were male gender [adjusted OR (AOR) 2.1 (95% confidence interval, 95% CI: 1.03-4.2), P = 0.040],
| INTRODUC TI ON
It is well known that human immunodeficiency virus (HIV) coinfection is associated with an increased risk of advanced liver disease in hepatitis C virus (HCV)-infected patients. [1] [2] [3] Thus, HIV coinfection accelerates fibrosis progression in chronic hepatitis C. 4 As a consequence, advanced fibrosis and cirrhosis are more frequent among HIV/HCVcoinfected patients than among HCV-monoinfected individuals. [1] [2] [3] [4] In the setting of cirrhosis, HIV/HCV-coinfected patients show worse clinical outcomes than HCV-monoinfected subjects. 5 Liver decompensations are more likely, and overall survival is poorer. 5, 6 For HIV/ HCV-coinfected patients with cirrhosis achieving SVR, the potential benefits of clearing HCV with treatment could be counterbalanced by a poorer recovery of liver function. Indeed, given that HIV coinfection enhances fibrosis progression, it might also impair the regression of fibrosis after SVR and, hence, the recovery of liver function.
In clinical trials with direct-acting antivirals (DAA), improvements in liver function among HCV-monoinfected individuals with cirrhosis have been found in up to two-thirds of patients at SVR4. 7 In real life, improvements in MELD score at SVR12 were detected less frequently among subjects with cirrhosis. 8 Importantly, the stage of cirrhosis of patients included in the NHS England expanded access program was more advanced than that of patients with cirrhosis recruited in clinical trials. [7] [8] [9] [10] [11] As stated above, HIV/HCV-coinfected patients show more advanced liver disease than HCV-monoinfected patients. This fact coupled with the potential for a slower regression of fibrosis could lead to worse liver function outcomes after DAA treatment in HIV/HCV coinfection. However, comparative data on changes in liver function as a consequence of DAA therapy in patients with cirrhosis due to HCV with and without HIV coinfection are, to the best of our knowledge, lacking. Because of these, we compared the changes in several markers of liver function between HCV-monoinfected and HIV/HCV-coinfected patients with cirrhosis who achieved SVR12 to all-oral DAA combinations.
| ME THODS

| Design
This was a study of two prospective cohorts. Individuals recruited in both the HEPAVIR cohort (clinicaltrials.gov ID: NCT02057003) and the GEHEP-MONO cohort (clinicaltrials.gov ID: NCT02333292)
were included in the present study. The HEPAVIR cohort recruits HIV/HCV-coinfected patients, and GEHEP-MONO cohort enrolls HCV-monoinfected patients attended in 33 infectious diseases units across Spain. All individuals in both cohorts with cirrhosis and who had achieved SVR12 to interferon-free DAA regimens were retrospectively analyzed for the present study. HIV-coinfected patients receiving atazanavir as a part of their antiretroviral therapy at baseline, before starting DAA, or during anti-HCV treatment were excluded from the study. Liver function worsening and improvement rates after responding to DAA are similar among HCV-monoinfected and HIV/HCV-coinfected cirrhotics. Gender, INR, bilirubin, and albumin levels were associated with liver function changes after response to DAAs.
| Definition of cirrhosis
K E Y W O R D S
cirrhosis, direct-acting antiviral agents, HIV/HCV, liver function parameters, Sustained virological response treatment, patients were evaluated at baseline, at the date of starting therapy, and at week 4 and week 12. After the scheduled end of therapy, patients were evaluated at week 12 post-treatment. SVR12
was defined as undetectable plasma HCV RNA 12 weeks after the scheduled end of therapy.
| Statistical analysis
The primary end-point was improvement in global liver function, Predictors of global liver function worsening were analyzed by a logistic regression analysis. Independent variables entered in logistic regression models were those associated with the primary endpoint, entered as dependent variable, with a univariate P-value < 0.2.
In addition, models were adjusted by age, gender, and HIV status.
Logistic regression models were also elaborated to assess associations with the secondary end-point. A receiver operating characteristic curve was generated using the probabilities of the end-point predicted by the logistic regression models, from which the area under the curve (AUROC) was calculated. Data were analyzed using IBM SPSS 23.0 version (IBM Corporation, Somers, NY, USA) and STATA 9.0 (StataCorp LP, College Station, TX, USA).
F I G U R E 1 Disposition of study patients
| Ethics
The study was carried out according to the Helsinki Declaration and was approved by the local Ethics Committee. All patients gave their written informed consent to participate in the study.
| RE SULTS
| Characteristics of the study population
Among patients with cirrhosis at baseline and evaluable SVR12 in- were excluded from the study (Table S1 ). The baseline characteristics of the study patients are summarized in Table 1 . Antiretroviral regimens used during DAA treatment are listed in and in 24 (12%) HCV-monoinfected patients. Baseline liver stiffness measurements were available in all study patients. All liver stiffness measurements were equal to or greater than 12.5 kPa. DAA regimens used by HIV status are shown in Table S3 .
| Baseline liver function
At baseline, HIV/HCV-coinfected patients tended to show worse liver function parameters ( Table 1 ). The CPT score was equal to 5 among 174 (65%) HIV/HCV-coinfected patients compared with 169 (77%) HCV-monoinfected patients (P = 0.004). The MELD score was significantly higher for the HIV/HCV-coinfected group.
HIV/HCV-coinfected individuals presented higher liver stiffness values and lower platelet counts than HCV-monoinfected subjects. Previous decompensations of cirrhosis showed a trend to higher frequency in the group with HIV coinfection and HCV coinfection. 
F I G U R E 2
F I G U R E 3 Proportion of patients with:
A, CPT score changes; B, MELD score changes by two or more points. CPT score changes were analyzed in patients with baseline CPT score greater than 5. MELD score changes were analyzed in patients with baseline MELD score greater than 7. Solid bars: HIV/HCV coinfection; white bars: HCV monoinfection
. .
TA B L E 2
Factors associated with improvement in liver function, as determined by a decrease in CPT score by 1 or more points and/or decrease in MELD score by 2 or more points, between baseline and SVR12 among patients with baseline CPT > 5 and/or MELD > 7 (n = 234) 
| Clinical outcome
Before starting therapy, 72 (15%) patients had a liver decompensation event. After starting therapy and until the date of SVR12, 11 (65%) of 17 patients who developed a decompensation of cirrhosis had suffered prior decompensations before starting DAA, four (67%) of six patients without HIV coinfection and seven (64%) of 11 patients with HIV coinfection. The types of decompensations observed during treatment were as follows: five (29%) ascites, five (29%) hepatocellular carcinoma, three (18%) hepatic encephalopathy, two (12%) nonobstructive jaundice, one (6%) gastrointestinal bleeding due to portal hypertension, and one (6%) hepatorenal syndrome.
| Prediction of improvement and worsening of liver function
Decreases in the CPT score by one point or more and/or MELD score by 2 points or more were associated with baseline bilirubin levels, INR, and creatinine levels in univariate analysis (Table 2) . Women showed a trend to a lower frequency of liver function improvement than men. After multivariate adjustment, male gender, baseline INR, and bilirubin levels were independently associated with liver function improvement ( Table 2 (Table S4 ). Among individuals with previous liver decompensations, only lower bilirubin levels were associated with liver function improvement (Table S4) .
Increases in the CPT score by 1 or more points and/or MELD score by 2 or more points and/or emerging liver decompensations were more frequent among patients with baseline serum albumin lower than 3.5 g/dL and those with baseline MELD score equal or greater than 18 (Table 3) . After multivariate analysis, only baseline serum albumin levels were independently associated with global worsening of liver function. HIV status was not associated with worsening of liver function.
| D ISCUSS I ON
From the start of DAA treatment to the date of SVR12 achievement, HIV/HCV-coinfected and HCV-monoinfected patients with cirrhosis
show similar rates of recovery in liver function parameters. In addition, the frequencies of overall liver function, as measured by CPT and MELD scores as well as by clinical outcome, improvement, and worsening after responding to DAA therapy are similar in patients with HCV-related cirrhosis with and without HIV coinfection.
The differences in liver function parameters and scores at baseline, before starting DAA combinations, between patients with and without HIV coinfection that we found in the present study were short-term benefit is translated into a similar reduction in the rate of liver events over time.
The rates of MELD improvement that we found in the present study are in agreement with most previous data in HCVmonoinfected patients. Thus, in the ALLY-1, C-SALT, and ASTRAL-4, the MELD decreased by one point or more in 45% to 54% individuals with cirrhosis at SVR12. 9, [16] [17] [18] The frequency of a MELD score increase by one point or more in those clinical trials ranged from 22% to 34%. 9, [16] [17] [18] The rate of a MELD score increase by 2 points or more in an observational study that included more advanced stages of disease, mostly decompensated cirrhosis, was 12%. 8 We found
here very similar figures for MELD worsening by two or more points, that is, 11% for the HIV-uninfected group and 9.8% for the HIV- 
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